CNS Pharmaceuticals, Inc. (CNSP) financial statements (2022 and earlier)

Company profile

Business Address 2100 WEST LOOP SOUTH
HOUSTON, TX 77027
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5,00514,0397,241
Cash and cash equivalents5,00514,0397,241
Prepaid expense2,4731,456653
Total current assets:7,47715,4967,894
Noncurrent Assets
Property, plant and equipment162318
Prepaid expense930  
Other undisclosed noncurrent assets334334 
Total noncurrent assets:1,28035818
TOTAL ASSETS:8,75715,8537,912
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,7481,466265
Accounts payable1,523946244
Accrued liabilities22552022
Debt388439 
Due to related parties  46
Total current liabilities:2,1361,905311
Noncurrent Liabilities
Total liabilities:2,1361,905311
Stockholders' equity
Stockholders' equity attributable to parent6,62213,9487,601
Common stock282416
Additional paid in capital41,57734,87019,073
Accumulated deficit(34,983)(20,946)(11,488)
Total stockholders' equity:6,62213,9487,601
TOTAL LIABILITIES AND EQUITY:8,75715,8537,912

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Operating expenses(14,027)(9,455)(3,833)
Operating loss:(14,027)(9,455)(3,833)
Nonoperating expense(9)(3)(44)
Interest and debt expense(9)(3)(26)
Net loss:(14,046)(9,461)(3,903)
Other undisclosed net income attributable to parent9326
Net loss available to common stockholders, diluted:(14,037)(9,458)(3,877)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Net loss:(14,046)(9,461)(3,903)
Comprehensive loss, net of tax, attributable to parent:(14,046)(9,461)(3,903)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: